Apr. 11, 2019


...."SMEs are the keystone to fuel the pipeline by providing new innovative compounds and technologies and conducting both early and clinical stage research", says Marc Gitzinger, CEO of BioVersys

On February 24th, 2017 BioVersys will be among the 30 speakers from all over Europe discussing current challenges in the antimicrobials market in Europe during the Berlin Conference on Novel Antimicrobials

Full article here